PR_Viola-Enters_UK_Avicanna
Avicanna Expands its Partnership with Viola Brands to the United Kingdom
07 févr. 2023 07h43 HE | Avicanna Inc.
The initial line of Viola-branded products will include proprietary formulations in vaporizer formats for patients with medical authorizations through the Special Access Program. The prescription...
Avicanna_Logo_Colour_WithTM-01.png
Avicanna Announces Warrant and Debenture Repricing and Amendments
30 janv. 2023 17h00 HE | Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
PR_site_Aureus-to-Spain_January-13-2023
Avicanna Subsidiary Santa Marta Golden Hemp S.A.S. Completes First Commercial Export of feminized Cannabis Seeds from Colombia to Spain
17 janv. 2023 07h30 HE | Avicanna Inc.
This export marks Avicanna’s 19th new international market for Avicanna and the 16th for Aureus branded products. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE...
Avicanna.png
Avicanna Announces Organizational Change in Avicanna LATAM S.A.S
30 déc. 2022 07h30 HE | Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
Avicanna.png
Avicanna Announces Promotion of Phillip Cardella to Chief Financial Officer and Closing of Non-Brokered Private Placement
21 déc. 2022 17h00 HE | Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
221214 AVCN NR Image
Avicanna and Santé Cannabis Initiate Real-World Evidence Study on Musculoskeletal Pain and Inflammation with the RHO Phyto™ CBG Transdermal Gel Topical Product
14 déc. 2022 07h33 HE | Avicanna Inc.
TORONTO, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on...
221128 AVCN NR Image 1
Avicanna Commercializes ‘Influid’, a Proprietary Water-soluble technology in the Canadian Market
29 nov. 2022 07h30 HE | Avicanna Inc.
Developed through Avicanna’s scientific platform, the patent-pending technology provides infusion of a range of cannabinoids into various beverages Initial commercial use of the technology is a THC...
Avicanna.png
Avicanna Reports Q3 2022 Financial Statement
14 nov. 2022 07h30 HE | Avicanna Inc.
TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY...
Avicanna.png
Avicanna Announces Closing of Non-Brokered Private Placement
11 nov. 2022 07h30 HE | Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
Avicanna.png
Avicanna Announces Extension of Term Loan
31 oct. 2022 17h00 HE | Avicanna Inc.
TORONTO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on...